Methods for addressing injection site reactions associated with the administration of bevemipretide

HK40137507APending Publication Date: 2026-09-11STEALTH BIOTHERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
HK62026126943
Authority / Receiving Office
HK · HK
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-25
Filing Date
2026-07-31
Publication Date
2026-09-11

Smart Images

  • Figure 00000055_0000
    Figure 00000055_0000
  • Figure 00000057_0000
    Figure 00000057_0000
  • Figure 00000058_0000
    Figure 00000058_0000
Patent Text Reader

Abstract

The present disclosure provides methods for treating, preventing, ameliorating, inhibiting or delaying the onset of injection site reactions associated with the subcutaneous administration of bevemipretide, or a pharmaceutically acceptable salt thereof. The methods may involve administration of inhibitors of the MRGPRX2 receptor and / or inhibitors of mast cell degranulation. In some cases, the methods involve administration of an effective amount of a flavonoid, a coumarin, a phenol, a terpenoid, mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice.
Need to check novelty before this filing date? Find Prior Art

Description

This disclosure provides methods for treating, preventing, improving, inhibiting, or delaying the onset of injection site reactions associated with subcutaneous administration of bevacizumab or a pharmaceutically acceptable salt thereof. The methods may involve administering an MRGPRX2 receptor inhibitor and / or a mast cell degranulation inhibitor. In some cases, the methods involve administering an effective amount of flavonoids, coumarins, phenols, terpenoids, mometasone furoate, tacrolimus, quercetin, diphenhydramine, and / or ice. Abstract

Claims

CLAIMSWhat is claimed is:

1. A method for treating, preventing, ameliorating, inhibiting or delaying the onset of injection site reactions associated with subcutaneous injections of bevemipretide, or a pharmaceutically acceptable salt thereof, administered to a subject in need thereof, comprising contacting a bevemipretide injection site or intended injection site with an effective amount of an inhibitor of a MRGPRX2 receptor.

2. The method of claim 1, wherein contacting the bevemipretide injection site or intended injection site with the inhibitor of the MRGPRX2 receptor treats, prevents, ameliorates, inhibits or delays the onset of mast cell degranulation in the subject.

3. The method of claims 1 or 2, wherein the method comprises contacting the bevemipretide injection site or intended injection site with an effective amount of a flavonoid, a coumarin, a phenol or a terpenoid as the inhibitor of a MRGPRX2 receptor.

4. The method of claim 3, wherein the flavonoid is luteolin (3 ',4', 5, 7- tetrahydroxyflavone), diosmetin (5,7,3 '-trihydroxy -4'-methoxyflavone), apigenin (4',5,7-trihydroxyflavone), quercetin (3,3',4',5,7-pentahydroxyflavone), fisetin (2- (3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one), kaempferol (3, 4', 5, 7- tetrahydroxyflavone), ginkgetin (7,4'-dimethylamentoflavone) or silymarin.

5. The method of claim 3, wherein the coumarin is scopletin (6-methoxy-7 hydroxycoumarin), scaporone (6,7-dimethoxycoumarin), artekeiskeanol A (7- {[(2E,6E)-8-Hydroxy-3,7-dimethylocta-2,6-dien-l-yl]oxy}-6-methoxy-2H-chromen- 2-one), selinidin ((8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-h]chromen-9-yl) 2- methylbut-2-enoate), 5-methoxy-8-(2-hydroxy-3-butoxy-3-methylbutyloxy)-psoralen, cinnamic acid ((2E)-3-phenylprop-2-enoic acid) or ellagic acid (2, 3,7,8- tetrahy droxy [ 1 ]benzopyrano[5 ,4, 3 -cde [ 1 ]benzopyran-5 , 10-dione).

6. The method of claim 3, wherein the phenol is magnolol (5,5'-di(prop-2-en-l-yl)[l,l'- biphenyl]-2,2'-diol), honokiol (3',5-di(prop-2-en-l-yl)[l,r-biphenyl]-2,4'-diol), resveratrol (5-[E-2-(4-hydroxyphenyl)ethen-l-yl]benzene-l,3-diol), polydatin (3,4',5- trihydroxystilbene-3-P-d-glucoside), curcumin ((lE,6E)-l,7-bis(4-hydroxy-3- methoxyphenyl)hepta- 1 ,6-diene-3 , 5 -di one), a-mangostin (1,3, 6-trihy droxy-7 -methoxy-2,8-bis(3-methylbut-2-en-l-yl)-9H-xanthen-9-one), P-mangostin (1,6- dihydroxy-3,7-dimethoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one) or y-mangostin ( 1 ,3 ,6,7-tetrahydroxy-2, 8-bi s(3 -methylbut-2-en- 1 -yl)-9H-xanthen-9-one) .

7. The method of claim 3, wherein the terpenoid is parthenolide ((la7?,4E,7a5,10aS,10b7?)-2,3,6,7,7a,8,10a,10b-octahydro-la,5-dimethyl-8-methylene- oxireno[9,l O]cyclodeca[l ,2-Z>]furan-9(l aH)-one), sinomenine, indoline (2,3-dihydro- 17 -indole) or xestospongin C ([lR-(lR,4aR,l lR,12aS,13S,16aS,23R,24aS)]- eicosahydro-5H, 17H- 1 ,23 : 11 , 13-diethano-2H, 14H-[ 1,11 ]dioxacycloeicosino[2,3 - b: 12,13-bl]dipyridine).

8. The method of any one of claims 3 to 7, wherein the bevemipretide injection site or intended injection site is contacted with the flavonoid, the coumarin, the phenol or the terpenoid prior to administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

9. The method of any one of claims 3 to 7, wherein the bevemipretide injection site or intended injection site is contacted with the flavonoid, the coumarin, the phenol or the terpenoid after administration of bevemipretide, or a pharmaceutically acceptable salt thereof10. The method of claims 1 or 2, wherein the method comprises contacting the bevemipretide injection site or intended injection site with an effective amount of mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice.

11. The method of claim 10, wherein mometasone furoate ointment is applied to the injection site to thereby contact the bevemipretide injection site or intended injection site with mometasone furoate.

12. The method of claim 10, wherein tacrolimus ointment or quercetin ointment is applied to the injection site to thereby contact the bevemipretide injection site or intended injection site with tacrolimus or quercetin.

13. The method of claim 10, wherein diphenhydramine or quercetin is administered systemically, optionally via oral administration, to the subject to thereby contact the bevemipretide injection site or intended injection site with diphenhydramine or quercetin.

14. The method of claim 10, wherein ice is applied to the injection site or intended injection site to thereby contact the bevemipretide injection site or intended injection site with the ice.

15. The method of claims 1 or 2, wherein the bevemipretide injection site or intended injection site is contacted with the mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice prior to administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

16. The method of claims 1 or 2, wherein the bevemipretide injection site or intended injection site is contacted with the mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice after administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

17. The method of any one of claims 1 to 16, wherein about 5mg to about 60mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the bevemipretide injection site.

18. A method for treating, preventing, ameliorating, inhibiting or delaying the onset of injection site reactions associated with subcutaneous injections of bevemipretide, or a pharmaceutically acceptable salt thereof, administered to a subject in need thereof, comprising contacting a bevemipretide injection site or intended injection site with an effective amount of an inhibitor of mast cell degranulation.

19. The method of claim 18, wherein the method comprises contacting the bevemipretide injection site or intended injection site with an effective amount of a flavonoid, a coumarin, a phenol or a terpenoid as the inhibitor of mast cell degranulation.

20. The method of claim 19, wherein the flavonoid is luteolin (3 ',4', 5,7- tetrahydroxyflavone), diosmetin (5,7,3 '-trihydroxy -4'-methoxyflavone), apigenin (4',5,7-trihydroxyflavone), quercetin (3,3',4',5,7-pentahydroxyflavone), fisetin (2- (3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one), kaempferol (3, 4', 5,7- tetrahydroxyflavone), ginkgetin (7,4'-dimethylamentoflavone) or silymarin.

21. The method of claim 19, wherein the coumarin is scopletin (6-methoxy-7 hydroxycoumarin), scaporone (6, 7-dimethoxy coumarin), artekeiskeanol A (7- {[(2E,6E)-8-Hydroxy-3,7-dimethylocta-2,6-dien-l-yl]oxy}-6-methoxy-2H-chromen- 2-one), selinidin ((8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-h]chromen-9-yl) 2- methylbut-2-enoate), 5-methoxy-8-(2-hydroxy-3-butoxy-3-methylbutyloxy)-psoralen,cinnamic acid ((2£)-3-phenylprop-2-enoic acid) or ellagic acid (2, 3,7,8- tetrahy droxy [ 1 ]benzopyrano[5 ,4, 3 -cde] [ 1 ]benzopyran-5 , 10-dione).

22. The method of claim 19, wherein the phenol is magnolol (5,5'-di(prop-2-en-l-yl)[l,T- biphenyl]-2,2'-diol), honokiol (3',5-di(prop-2-en-l-yl)[l,r-biphenyl]-2,4'-diol), resveratrol (5-[E-2-(4-hydroxyphenyl)ethen-l-yl]benzene-l,3-diol), polydatin (3,4',5- trihydroxystilbene-3-P-d-glucoside), curcumin ((lE,6E)-l,7-bis(4-hydroxy-3- methoxyphenyl)hepta- 1 ,6-diene-3 , 5 -di one), a-mangostin (1,3, 6-trihy droxy-7 - methoxy-2,8-bis(3-methylbut-2-en-l-yl)-9H-xanthen-9-one), P-mangostin (1,6- dihydroxy-3,7-dimethoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one) or y-mangostin ( 1 ,3 ,6,7-tetrahydroxy-2, 8-bi s(3 -methylbut-2-en- 1 -yl)-9H-xanthen-9-one) .

23. The method of claim 19, wherein the terpenoid is parthenolide((1 aR,4E,7aS, 1 OaS, 10bJ?)-2,3,6,7,7a,8, 1 Oa, 1 Ob-octahydro- 1 a,5-dimethyl-8-methylene- oxireno[9,10]cyclodeca[l,2-Z>]furan-9(laH)-one), sinomenine, indoline (2,3-dihydro- 177-indole) or xestospongin C ([lR-(lR,4aR,l lR,12aS,13S,16aS,23R,24aS)]- eicosahydro-5H, 17H- 1 ,23 : 11 , 13-diethano-2H, 14H-[ 1,11 ]dioxacycloeicosino[2,3 - b : 12, 13 -b 1 ] di pyridine) .

24. The method of any one of claims 19 to 23, wherein the bevemipretide injection site or intended injection site is contacted with the flavonoid, the coumarin, the phenol or the terpenoid prior to administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

25. The method of any one of claims 19 to 23, wherein the bevemipretide injection site or intended injection site is contacted with the flavonoid, the coumarin, the phenol or the terpenoid after administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

26. The method of claims 18 or 19, wherein the method comprises contacting the bevemipretide injection site or intended injection site with an effective amount of mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice.

27. The method of claim 26, wherein mometasone furoate ointment is applied to the injection site or intended injection site to thereby contact the bevemipretide injection site with mometasone furoate.

28. The method of claim 26, wherein tacrolimus ointment or quercetin ointment is applied to the injection site or intended injection site to thereby contact the bevemipretide injection site with tacrolimus or quercetin.

29. The method of claim 26, wherein diphenhydramine or quercetin is administered systemically, optionally via oral administration, to the subject to thereby contact the bevemipretide injection site or intended injection site with diphenhydramine or quercetin.

30. The method of claim 26, wherein ice is applied to the injection site or intended injection site to thereby contact the bevemipretide injection site with the ice.

31. The method of any one of claims 26 to 30, wherein the bevemipretide injection site or intended injection site is contacted with the mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice prior to administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

32. The method of any one of claims 26 to 30, wherein the bevemipretide injection site or intended injection site is contacted with the mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice after administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

33. The method of any one of claims 18 to 32, wherein about 5mg to about 60mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the bevemipretide injection site.

34. A method for treating, preventing, ameliorating, inhibiting or delaying the onset of injection site reactions associated with subcutaneous injections of bevemipretide, or a pharmaceutically acceptable salt thereof, administered to a subject in need thereof, comprising contacting a bevemipretide injection site or intended injection site with a flavonoid, a coumarin, a phenol or a terpenoid.

35. The method of claim 34, wherein the flavonoid is luteolin (3 ',4', 5,7- tetrahydroxyflavone), diosmetin (5,7,3 '-trihydroxy-4'-methoxyflavone), apigenin (4',5,7-trihydroxyflavone), quercetin (3,3',4',5,7-pentahydroxyflavone), fisetin (2- (3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one), kaempferol (3, 4', 5,7- tetrahydroxyflavone), ginkgetin (7,4'-dimethylamentoflavone) or silymarin.

36. The method of claim 34, wherein the coumarin is scopletin (6-methoxy-7 hydroxycoumarin), scaporone (6,7-dimethoxycoumarin), artekeiskeanol A (7- {[(2E,6E)-8-Hydroxy-3,7-dimethylocta-2,6-dien-l-yl]oxy}-6-methoxy-2H-chromen- 2-one), selinidin ((8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-h]chromen-9-yl) 2- methylbut-2-enoate), 5-methoxy-8-(2-hydroxy-3-butoxy-3-methylbutyloxy)-psoralen, cinnamic acid ((2E)-3-phenylprop-2-enoic acid) or ellagic acid (2, 3,7,8- tetrahy droxy [ 1 ]benzopyrano[5 ,4, 3 -cde\ [ 1 ]benzopyran-5 , 10-dione).

37. The method of claim 34, wherein the phenol is magnolol (5,5'-di(prop-2-en-l-yl)[l,r- biphenyl]-2,2'-diol), honokiol (3',5-di(prop-2-en-l-yl)[l,l '-biphenyl]-2,4'-diol), resveratrol (5-[E-2-(4-hydroxyphenyl)ethen-l-yl]benzene-l,3-diol), polydatin (3,4',5- trihydroxystilbene-3-P-d-glucoside), curcumin ((lE,6£)-l,7-bis(4-hydroxy-3- methoxyphenyl)hepta- 1 ,6-diene-3 , 5 -di one), a-mangostin (1,3, 6-trihy droxy-7 - methoxy-2,8-bis(3-methylbut-2-en-l-yl)-9H-xanthen-9-one), P-mangostin (1,6- dihydroxy-3,7-dimethoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one) or y-mangostin ( 1 ,3 ,6,7-tetrahydroxy-2, 8-bi s(3 -methylbut-2-en- 1 -yl)-9H-xanthen-9-one) .

38. The method of claim 34, wherein the terpenoid is parthenolide ((la ,4E',7a<S',10aS,10bA)-2,3,6,7,7a,8,10a,10b-octahydro-la,5-dimethyl-8-methylene- oxireno[9, 10]cyclodeca[l,2-Z>]furan-9( l a7 / -one), sinomenine, indoline (2,3-dihydro- 1 / 7-indole) or xestospongin C ([lR-(lR,4aR,l !R,12aS,13S,16aS,23R,24aS)]- eicosahydro-5H, 17H- 1 ,23 : 11 , 13-diethano-2H, 14H-[ 1,11 ]dioxacycloeicosino[2,3 - b: 12,13-bl]dipyridine).

39. The method of any one of claims 34 to 38, wherein the bevemipretide injection site or intended injection site is contacted with the flavonoid, the coumarin, the phenol or the terpenoid prior to administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

40. The method of any one of claims 34 to 38, wherein the bevemipretide injection site or intended injection site is contacted with the flavonoid, the coumarin, the phenol or the terpenoid after administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

41. The method of any one of claims 34 to 40, wherein about 5mg to about 60mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the injection site.

42. A method for treating, preventing, ameliorating, inhibiting or delaying the onset of injection site reactions associated with subcutaneous injections of bevemipretide, or a pharmaceutically acceptable salt thereof, administered to a subject in need thereof, comprising contacting a bevemipretide injection site or intended injection site with mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice.

43. The method of claim 42, wherein the bevemipretide injection site or intended injection site is contacted with mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice prior to administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

44. The method of claim 42, wherein the bevemipretide injection site or intended injection site is contacted with mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice after administration of bevemipretide, or a pharmaceutically acceptable salt thereof.

45. The method of any one of claims 42 to 44, wherein mometasone furoate ointment is applied to the injection site or intended injection site to thereby contact the bevemipretide injection site with the mometasone furoate ointment.

46. The method of any one of claims 42 to 44, wherein tacrolimus ointment is applied to the injection site or intended injection site to thereby contact the bevemipretide injection site with tacrolimus ointment or quercetin ointment.

47. The method of any one of claims 42 to 44, wherein diphenhydramine or quercetin is administered systemically to the subject to thereby contact the bevemipretide injection site or intended injection site with the diphenhydramine or quercetin.

48. The method of any one of claims 42 to 43, wherein ice is applied to the injection site or intended injection site to thereby contact the bevemipretide injection site with the ice.

49. The method of any one of claims 34 to 47, wherein from about 5mg to about 60mg, of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

50. The method of claim 49, wherein about 5mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

51. The method of claim 49, wherein about lOmg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject52. The method of claim 49, wherein about 20mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

53. The method of claim 49, wherein about 30mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

54. The method of claim 49, wherein about 40mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

55. The method of claim 49, wherein about 50mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

56. The method of claim 49, wherein about 60mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

57. A method compri sing : a) subcutaneously administering an effective amount of bevemipretide, or a pharmaceutically acceptable salt thereof, to a subject; and b) also administering to said subject an inhibitor of a MRGPRX2 receptor and / or inhibitor of mast cell degranulation; wherein steps a) and b) can be performed in either order or simultaneously.

58. The method of claim 57, wherein step (a) is performed prior to performing step (b).

59. The method of claim 57, wherein step (b) is performed prior to performing step (a).

60. The method of claim 57, wherein step (a) and step (b) are performed simultaneously or substantially simultaneously.

61. The method of any one of claims 57 to 60, wherein the subject is administered an inhibitor of the MRGPRX2 receptor.

62. The method of any one of claims 57 to 60, wherein the subject is administered an inhibitor of mast cell degranulation.

63. The method of any one of claims 57 to 62, wherein the inhibitor of the MRGPRX2 receptor or the inhibitor of mast cell degranulation is a flavonoid, a coumarin, a phenol or a terpenoid.

64. The method of claim 63, wherein the flavonoid is luteolin (3', 4', 5, 7- tetrahydroxyflavone), diosmetin (5,7,3 '-trihydroxy -4'-methoxyflavone), apigenin (4',5,7-trihydroxyflavone), quercetin (3,3’,4',5,7-pentahydroxyflavone), fisetin (2- (3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one), kaempferol (3, 4', 5, 7- tetrahydroxyflavone), ginkgetin (7,4'-dimethylamentoflavone) or silymarin.

65. The method of claim 63, wherein the coumarin is scopletin (6-methoxy-7 hydroxycoumarin), scaporone (6, 7-dimethoxy coumarin), artekeiskeanol A (7- {[(2E,6E)-8-Hydroxy-3,7-dimethylocta-2,6-dien-l-yl]oxy}-6-methoxy-2H-chromen- 2-one), selinidin ((8,8-dimethyl-2-oxo-9,10-dihydropyrano[2,3-h]chromen-9-yl) 2- methylbut-2-enoate), 5-methoxy-8-(2-hydroxy-3-butoxy-3-methylbutyloxy)-psoralen, cinnamic acid ((2£)-3-phenylprop-2-enoic acid) or ellagic acid (2, 3,7,8- tetrahy droxy [ 1 ]benzopyrano[5 ,4, 3 -cde\ [ 1 ]benzopyran-5 , 10-dione).

66. The method of claim 63, wherein the phenol is magnolol (5,5'-di(prop-2-en-l-yl)[l, 1 '- biphenyl]-2,2'-diol), honokiol (3',5-di(prop-2-en-l-yl)[l,l '-biphenyl]-2,4'-diol), resveratrol (5-[E-2-(4-hydroxyphenyl)ethen-l-yl]benzene-l,3-diol), polydatin (3,4',5- trihydroxystilbene-3-P-d-glucoside), curcumin ((lE,6£)-l,7-bis(4-hydroxy-3- methoxyphenyl)hepta- 1 ,6-diene-3 , 5 -di one), a-mangostin (1,3, 6-trihy droxy-7 - methoxy-2,8-bis(3-methylbut-2-en-l-yl)-9H-xanthen-9-one), P-mangostin (1,6- dihydroxy-3, 7-dimethoxy -2, 8-bis(3-methylbut-2-enyl)xanthen-9-one) or y-mangostin ( 1 ,3 ,6,7-tetrahydroxy-2, 8-bi s(3 -methylbut-2-en- 1 -yl)-9H-xanthen-9-one) .

67. The method of claim 63, wherein the terpenoid is parthenolide((1 aR,4E,7aS,l OaS,l 0b ?)-2,3,6,7,7a,8,l Oa,l Ob-octahydro-1 a,5-dimethyl-8-methylene- oxireno[9,10]cyclodeca[l,2-Z>]furan-9(la / 7)-one), sinomenine, indoline (2,3-dihydro- 177-indole) or xestospongin C ([lR-(lR,4aR,l !R,12aS,13S,16aS,23R,24aS)]- eicosahydro-5H, 17H- 1 ,23 : 11 , 13-diethano-2H, 14H-[ 1,11 ]dioxacycloeicosino[2,3 - b : 12, 13 -b 1 ] di pyridine) .

68. The method of any one of claims 57 to 62, wherein an effective amount of mometasone furoate, tacrolimus, quercetin, diphenhydramine and / or ice is administered to the subject as the inhibitor of the MRGPRX2 receptor or the inhibitor of mast cell degranulation.

69. The method of any one of claims 57 to 68, wherein the subject is human.

70. The method of any one of claims 57 to 69, wherein from about 5 mg to about 60mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

71. The method of claim 70, wherein about 5mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

72. The method of claim 70, wherein about lOmg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

73. The method of claim 70, wherein about 20mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

74. The method of claim 70, wherein about 40mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

75. The method of claim 70, wherein about 50mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

76. The method of claim 70, wherein about 60mg of bevemipretide, or a pharmaceutically acceptable salt thereof, is subcutaneously administered to the subject.

77. The method of any one of claims 1 to 76, wherein the subject has been diagnosed with diabetic macular edema, macular degeneration, age-related macular degeneration, glaucoma, diabetic retinopathy or retinitis pigmentosa.

78. The method of claim 77, wherein the subject has been diagnosed as having age- related macular degeneration (AMD).

79. The method of claim 78, wherein the subject has drusen.

80. The method of claim 78 or 79, wherein the subject has been diagnosed with geographic atrophy (GA).

81. The method of any one of claims 1 to 76, wherein the subject has been diagnosed with amyotrophic lateral sclerosis (ALS), Parkinson’s disease (PD), PD with dementia, dementia with Lewy bodies, Multiple System Atrophy, Frontotemporal Lobar Degeneration (FTLD) or other disease where TDP-43, Tau protein and a- sy nuclein are associated with the disease pathology